A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Affiliation auteurs!!!! Error affiliation !!!!
TitreA Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Type de publicationJournal Article
Year of Publication2019
AuteursKalakonda N, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Lavee O, Maerevoet M, Zijlstra J, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho J-M, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos T, Warzocha K, McCarthy D, Ma X, Corona K, Saint-Martin J-R, Joshi A, Shah J, Van Den Neste E, Canales M
JournalCLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume19
PaginationS248-S249
Date PublishedSEP
Type of ArticleMeeting Abstract
ISSN2152-2650
Mots-clésABCL, aggressive B-cell lymphoma, diffuse large B-cell lymphoma, selinexor, XPO1 inhibitor
DOI10.1016/j.clml.2019.07.153